- Home
- STGW vs CVAC Comparison
STGW vs CVAC Comparison
Compare STGW & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- CVAC
- Stock Information
- Founded
- STGW 1980
- CVAC 2000
- Country
- STGW United States
- CVAC Germany
- Employees
- STGW N/A
- CVAC N/A
- Industry
- STGW
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- CVAC Health Care
- Exchange
- STGW Nasdaq
- CVAC Nasdaq
- Market Cap
- STGW 1.4B
- CVAC 1.2B
- IPO Year
- STGW N/A
- CVAC 2020
- Fundamental
- Price
- STGW $5.21
- CVAC $5.36
- Analyst Decision
- STGW Buy
- CVAC Hold
- Analyst Count
- STGW 5
- CVAC 3
- Target Price
- STGW $8.17
- CVAC $6.83
- AVG Volume (30 Days)
- STGW 1.0M
- CVAC 475.8K
- Earning Date
- STGW 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- STGW N/A
- CVAC N/A
- EPS Growth
- STGW N/A
- CVAC N/A
- EPS
- STGW N/A
- CVAC 1.01
- Revenue
- STGW $2,858,547,000.00
- CVAC $599,540,810.00
- Revenue This Year
- STGW $4.85
- CVAC N/A
- Revenue Next Year
- STGW $8.79
- CVAC $23.95
- P/E Ratio
- STGW N/A
- CVAC $5.32
- Revenue Growth
- STGW 9.37
- CVAC 675.15
- 52 Week Low
- STGW $4.03
- CVAC $2.37
- 52 Week High
- STGW $8.18
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- STGW 41.82
- CVAC 46.28
- Support Level
- STGW $5.12
- CVAC $5.32
- Resistance Level
- STGW $5.62
- CVAC $5.41
- Average True Range (ATR)
- STGW 0.20
- CVAC 0.04
- MACD
- STGW -0.06
- CVAC -0.00
- Stochastic Oscillator
- STGW 14.52
- CVAC 44.44
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.